Please assess the completion status of the following clinical trial:

Trial Title: 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females \> 16 and \< 80 years of age.~2. Blood pressure \< 140/90 mmHg.~3. Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ≥ 60 ml/min.~4. Bleeding time, prothrombin time, partial thromboplastin time, platelets and fibrinogen in the normal range.~Exclusion Criteria:~1. Biopsy of transplant kidney~2. Poorly controlled hypertension~3. Single kidney~4. Renal cancer~5. Hydro/pyonephrosis~6. Renal size significantly reduced~7. Severe obesity~8. Coagulation disorder~9. Serum creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 ml/min

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Saline solution (Type: PLACEBO_COMPARATOR): patients treated with 1 ml of s.c. saline solution
- DDAVP (Type: EXPERIMENTAL): treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).